Israeli-Canadian biotech psychedelics developer Clearmind Medicine Inc. (OTC:CMNDF) together with clinical-stage cannabinoid pharma company SciSparc Ltd. (NASDAQ:SPRC) announced that their collaborative study of cocaine addiction treatment with the non-hallucinogenic psychedelic compound MEAI (5-methoxy-2-aminoindane) has shown additional positive pre-clinical results.
The trial was led by Professor Gal Yadid and his team from the Gonda Multidisciplinary Brain Research Center at Bar Ilan University in Ramat Gan, Israel. Its design was set within a self-administration paradigm, the gold-standard model for examining drug addiction based on operant conditioning.
